Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Astaxanthin Supplementation in Cyclists

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Maastricht University Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01241877
First received: November 15, 2010
Last updated: April 19, 2011
Last verified: April 2011

November 15, 2010
April 19, 2011
November 2010
June 2011   (final data collection date for primary outcome measure)
time trial performance [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
time trial performance
Same as current
Complete list of historical versions of study NCT01241877 on ClinicalTrials.gov Archive Site
substrate use [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Astaxanthin Supplementation in Cyclists
Not Provided

Background of the study:

Astaxanthin has been shown to be a powerfull anti-oxidant. Health benefits have been shown in animals and humans. Exercise enhancing effects have been shown in animals via enhancement of fat oxidation. We want to examine the effects of 4 weeks of astaxanthin supplementation on fat oxidation and cycling performance in trained cyclists

Objective of the study:

To test the hypothesis that 4 weeks supplementation with astaxanthin will improve fat oxidation and improve exercise performance in trained cyclists

Study design:

Double blind, placebo controlled study.

Study population:

Well trained cyclists between 18-30 years old

Intervention (if applicable):

astaxanthin (20 mg/day) or placebo for 4 weeks

Primary study parameters/outcome of the study:

performance on a time trial after 90 min steady state exercise.

Secundary study parameters/outcome of the study (if applicable):

substrate use plasma glucose plasma lactate plasma free fatty acid plasma astaxanthin

Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):

The risks involved in participating in this experiment are minimal. Astaxanthin has been shown to be safe. Insertion of the catheters in a vein is comparable to a normal blood draw and the only risk is of a small local haematoma.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Athletic Performance
  • Dietary Supplement: astaxanthin
    astaxanthin
  • Dietary Supplement: placebo
    placebo
  • Experimental: astaxanthin
    Intervention: Dietary Supplement: astaxanthin
  • Placebo Comparator: placebo
    Intervention: Dietary Supplement: placebo
Klinkenberg LJ, Res PT, Haenen GR, Bast A, van Loon LJ, van Dieijen-Visser MP, Meex SJ. Effect of antioxidant supplementation on exercise-induced cardiac troponin release in cyclists: a randomized trial. PLoS One. 2013 Nov 19;8(11):e79280. doi: 10.1371/journal.pone.0079280. eCollection 2013.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
24
Not Provided
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy
  • Male
  • Age between 18 and 30 years
  • Endurance trained (≥3 sessions of endurance exercise per week)
  • VO2 max ≥ 50 ml/kg/min
  • Training history of more than one year of ≥3 sessions of endurance exercise per week
  • BMI <25 kg/m2

Exclusion Criteria:

  • Use of medication
  • Smoking
Male
18 Years to 30 Years
Yes
Contact: Peter Res, MSc +3143381383 peter.res@maastrichtuniversity.nl
Netherlands
 
NCT01241877
MEC 10-3-068
No
Peter Res, MUMC
Maastricht University Medical Center
Not Provided
Not Provided
Maastricht University Medical Center
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP